Skip to main content

Table 2 Included studies: interventions and outcomes assessed in the NMA

From: Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Studies included

Interventions studied and assessed in the NMA

Pain freedom at 2 hours

Pain relief at 2 hours

Pain relief at 1 hour

MBS freedom at 2 hours

Sustained pain freedom over 24 hours

Pain freedom at 30 min

Pain freedom at 1 hour

MBS freedom at 1 hour

Pain relief at 30 min

Lasmiditan vs placebo

 SAMURAI Kuca et al. 2018 [15]

Lasmiditan 100 mg, 200 mg

 SPARTAN Goadsby et al. 2019 [16]

Lasmiditan 50 mg, 100 mg, 200 mg

 CENTURION Ashina et al. 2021 [17]

Lasmiditan 100 mg, 200 mg

 MONONOFU Sakai et al. 2021 [18]

Lasmiditan 50 mg, 100 mg, 200 mg

Färkkilä et al. 2012 [19]

Lasmiditan 50 mg, 100 mg, 200 mg

       

Rimegepant vs placebo

 Study 301 Lipton et al. 2018 [20]

Rimegepant 75 mg tablets

 

    

 Study 302 Lipton et al. 2019 [21]

Rimegepant 75 mg tablets

 

    

 Study 303 Croop et al. 2019 [22]

Rimegepant 75 mg ODT

   

Marcus et al. 2014 [23]

Rimegepant 75 mg tablets

  

    

Ubrogepant vs placebo

 ACHIEVE I Dodick et al. 2019 [24]

Ubrogepant 50 mg, 100 mg

 

    

 ACHIEVE II Lipton et al. 2019 [25]

Ubrogepant 25 mg, 50 mg

 

    

 Voss et al. 2016 [26]

Ubrogepant 25 mg, 50 mg, 100 mg

  

    

 ACHIEVE I + ACHIEVE II pooled data Goadsby et al. 2021 [27]

Ubrogepant 50 mg

 

 

  1. Bold ticks denote the primary endpoint(s) of the study
  2. MBS most bothersome symptom, NMA network meta-analysis, ODT oral disintegrating tablet